Amgen

Amgen Reports Strong Q3 2025 with 10% Revenue Growth, 14% Volume Growth

安进

Amgen's 15min chart shows Bollinger Bands Narrowing and KDJ Death Cross.

Amgen: BMO Capital Maintains Outperform, Raises PT to $372 from $335

Gregory Lynn pleads guilty to breaching intervention order, death threats against ex-wife

Amgen Revolutionizes Drug Discovery with AI and Generative Biology

Catalyst<ul> <li>Net inflows across all fund size buckets suggest positive institutional interest in AMGN.</li></ul>Risk<ul> <li>The technical outlook remains weak with bearish signals dominant and no clear directional trend.</li> <li>A MACD Death Cross occurred on December 1, indicating a potential continuation of bearish momentum.</li></ul>

Key Factors

Amgen faces a $10.7 billion tax liability lawsuit as a federal judge denies its motion to dismiss the class-action case citing inadequate shareholder disclosure. BMO Capital upgrades Amgen to Outperform and raises its price target to $372 from $335 amid clinical and strategic momentum. Amgen reports 10% revenue growth in the first nine months of 2025 driven by 14% volume growth and strong performance across 16 products. Amgen leverages AI and generative biology to accelerate protein engineering, cutting discovery timelines in half and tripling engineering speed.

AMGN News